Artivion Announces Its Participation in Major Investor Conferences in November 2026

Artivion's Upcoming Engagement in Investor Conferences

Artivion, Inc., a prominent player in the cardiac and vascular surgery landscape, has revealed its participation in two upcoming investor conferences slated for November 2026. This initiative underscores the company's commitment to transparency and communication with stakeholders regarding its innovative medical solutions, primarily focused on treating aortic diseases.

The first conference, which will be held at the prestigious Lotte New York Palace Hotel, is the Stifel 2026 Healthcare Conference. Scheduled for November 10, 2026, Artivion's management team is set to deliver their presentation starting at 11:20 a.m. ET. This platform offers an opportunity for investors and industry professionals to gain insights into Artivion's strategic direction and its cutting-edge advancements in medical devices.

Following this, on November 11, 2026, Artivion will present at the 20th Annual Canaccord Genuity MedTech, Diagnostics, and Digital Health Services Forum. This event will take place at the Westin New York Grand Central Hotel, with the presentation kicking off at 8:00 a.m. ET. Both presentations will be accessible to a wider audience via live webcasts hosted on Artivion's official website. Investors and other interested parties can also access archived versions of these webcasts for 90 days post-event.

Artivion is based in suburban Atlanta, Georgia, and specializes in developing innovative solutions that address complex challenges faced by cardiac and vascular surgeons. The company offers a comprehensive range of products designed specifically for aortic disease treatment, including aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues. With a global presence in over 100 countries, Artivion strives to improve patient care through its sophisticated medical devices.

In the wake of recent advancements and the company’s focus on expanding its portfolio, these conferences serve as crucial platforms for Artivion to engage with investors. The presentations will likely touch on the company's latest innovations, clinical data, and future strategies aimed at enhancing the quality of life for patients suffering from aortic diseases.

Artivion’s proactive approach in reaching out to the investment community reflects its dedication to transparency and investor relations. By participating in these significant industry events, the company aims to nurture strong relationships with stakeholders and maintain open lines of communication regarding its growth and development.

As the date for these conferences approaches, stakeholders and interested attendees are encouraged to stay updated through Artivion's website for further details, including link access to the webcasts and additional information on the company’s efforts to address aortic disease challenges.

For further inquiries, Artivion has made available contact points through their investor relations team, ensuring that all questions regarding the upcoming conferences or the company’s product offerings can be addressed promptly.

In conclusion, Artivion’s participation in the upcoming investor conferences signifies not just an opportunity for engagement but also an ongoing commitment to fostering innovation in the medical device sector, especially in the realm of cardiac and vascular health.